Navigation Links
Gauze-based NPWT Capable of Achieving Same Treatment Goals as Foam-based NPWT
Date:10/24/2009

ST. PETERSBURG, Fla., Oct. 23 /PRNewswire-FirstCall/ -- The Advanced Wound Management Division of Smith & Nephew, Inc., a subsidiary of Smith & Nephew Plc (LSE: SN; NYSE: SNN), highlighted the results of a multi-center study which demonstrates that gauze-based Negative Pressure Wound Therapy (NPWT) achieves many of the common treatment goals defined for foam-based NPWT systems. These goals include a reduction in wound dimension, exudate, and improvement in granulation tissue. A second poster highlighting a sub-set of patients in the same study found that skin graft take was dramatically enhanced and care facilitated by gauze-based NPWT.

The results of this study were presented in a poster session today at the 24th Annual Clinical Symposium on Advances in Skin and Wound Care in San Antonio, Texas.

The prospective, multi-center clinical evaluation assessed 131 non-grafted patients at 21 centers in the United States, Canada, United Kingdom, Saudi Arabia and the United Arab Emirates. Its results included:

  • Wound dimensions were all significantly reduced during gauze-based NPWT (p<0.001). A weekly percentage reduction in wound area, depth and volume of 8.3%, 15.8% and 20.5% respectively was observed;
  • There was a significant reduction (p<0.001) in wound exudate levels from baseline to treatment discontinuation;
  • There was also a significant increase (p=0.007) in the percentage area of the wound bed composed of red granulation tissue over the course of gauze-based NPWT.

"Gauze-based NPWT can be used to address many of the treatment goals commonly defined at the onset of applying other NPWT systems," said Dr. Raymond Dunn, Chairman of Plastic Surgery, University of Massachusetts and lead author of the poster. "Clinicians in this study found the gauze-based negative pressu
'/>"/>

SOURCE Smith & Nephew Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
2. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
3. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... SHANGHAI , Oct. 22, 2014   ... and WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials ... Under the terms of the collaboration, Foundation Medicine will ... of Foundation Medicine,s FoundationOne® assay at the WuXi Genome ...
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... III TRIAL SHOW SIGNIFICANT, DECREASES IN PAIN AND ... ... , PALO ALTO, Calif., and BRUSSELS, Belgium, Nov. 20 /PRNewswire-FirstCall/,-- ... UCB),announced today positive preliminary top-line results from the first of two,Phase III ...
... Bionovo, Inc.,(Nasdaq: BNVI ) announced the company ... lead drug candidate for advanced metastatic breast,cancer, BZL101, at the ... The Company,s oral presentation was selected,as a top scoring abstract ... of the,SIO Session on November 20, 2008. , ...
Cached Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... Mission Viejo, CA (PRWEB) October 22, 2014 ... that Jay Cormier, Sr. Vice President of Sales, will ... at the upcoming Meetings Technology Expo on October 28, ... will also be hosting a booth as well as ... on how Lintelus Meeting can create a more engaging ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... could be a new way to help prevent heart disease. ... high-density lipoprotein levels, also known as good cholesterol. Statins have ... disease. They are commonly used to lower low-density lipoprotein (LDL) ... a low level of good cholesterol. In fact, a low ...
... examine the initial mammogram immediately so any follow-up tests ... Between 5 percent and 11 percent of all screening ... for a follow-up mammogram. Many abnormal mammograms turn out ... a breast cancer diagnosis within one year. Even when ...
... examine whether current procedures to treat sore throats were ... an estimated 6.7 million annual sore throat patients, 70 ... of throat cultures and rapid tests to detect streptococcus ... medical help for their sore throats. ,After sampling ...
... performing CPR on heart attack victims found they regularly ... by American Heart Association CPR standards.While the standards call ... personnel were delivering on average 37 -- essentially causing ... to follow the guidelines, they gave about 22 breaths ...
... show attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent ... that increased attention problems at age 7 among kids was ... and toddlers.The study tracked the number of hours kids watched ... about two hours of television a day. Three-year-olds watched about ...
... fast track to heart disease, say researchers based on recent ... risk can be significantly reduced. ,Researchers used two noninvasive ... that leads to heart attacks and stroke -- in the ... had not yet entered puberty, their test results were similar ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: